Novartis RNA pullback gives biotech stocks whiplash
This article was originally published in Scrip
Novartis stopped short of saying it has given up on RNA therapeutics entirely, but the company's pullback from the sector hurt several public biotechnology firms whose stocks declined in the US based on statements from the Swiss drug maker.
You may also be interested in...
The RNAi developer is preparing for Phase I clinical trials of three product candidates coming out of a next-generation technology platform. After a decade of RNAi development, CEO Douglas Fambrough says Dicerna is ready to earn back its place as a valuable biotech.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.